Cargando…

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches

The development of stabilized recombinant HIV envelope trimers that mimic the virion surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV vaccine. However, there is limited experience with recombinant trimers as immunogens in nonhuman primates, which are typically us...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauthner, Matthias, Havenar-Daughton, Colin, Sok, Devin, Nkolola, Joseph P., Bastidas, Raiza, Boopathy, Archana V., Carnathan, Diane G., Chandrashekar, Abishek, Cirelli, Kimberly M., Cottrell, Christopher A., Eroshkin, Alexey M., Guenaga, Javier, Kaushik, Kirti, Kulp, Daniel W., Liu, Jinyan, McCoy, Laura E., Oom, Aaron L., Ozorowski, Gabriel, Post, Kai W., Sharma, Shailendra K., Steichen, Jon M., de Taeye, Steven W., Tokatlian, Talar, Torrents de la Peña, Alba, Butera, Salvatore T., LaBranche, Celia C., Montefiori, David C., Silvestri, Guido, Wilson, Ian A., Irvine, Darrell J., Sanders, Rogier W., Schief, William R., Ward, Andrew B., Wyatt, Richard T., Barouch, Dan H., Crotty, Shane, Burton, Dennis R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483234/
https://www.ncbi.nlm.nih.gov/pubmed/28636956
http://dx.doi.org/10.1016/j.immuni.2017.05.007
_version_ 1783245718141534208
author Pauthner, Matthias
Havenar-Daughton, Colin
Sok, Devin
Nkolola, Joseph P.
Bastidas, Raiza
Boopathy, Archana V.
Carnathan, Diane G.
Chandrashekar, Abishek
Cirelli, Kimberly M.
Cottrell, Christopher A.
Eroshkin, Alexey M.
Guenaga, Javier
Kaushik, Kirti
Kulp, Daniel W.
Liu, Jinyan
McCoy, Laura E.
Oom, Aaron L.
Ozorowski, Gabriel
Post, Kai W.
Sharma, Shailendra K.
Steichen, Jon M.
de Taeye, Steven W.
Tokatlian, Talar
Torrents de la Peña, Alba
Butera, Salvatore T.
LaBranche, Celia C.
Montefiori, David C.
Silvestri, Guido
Wilson, Ian A.
Irvine, Darrell J.
Sanders, Rogier W.
Schief, William R.
Ward, Andrew B.
Wyatt, Richard T.
Barouch, Dan H.
Crotty, Shane
Burton, Dennis R.
author_facet Pauthner, Matthias
Havenar-Daughton, Colin
Sok, Devin
Nkolola, Joseph P.
Bastidas, Raiza
Boopathy, Archana V.
Carnathan, Diane G.
Chandrashekar, Abishek
Cirelli, Kimberly M.
Cottrell, Christopher A.
Eroshkin, Alexey M.
Guenaga, Javier
Kaushik, Kirti
Kulp, Daniel W.
Liu, Jinyan
McCoy, Laura E.
Oom, Aaron L.
Ozorowski, Gabriel
Post, Kai W.
Sharma, Shailendra K.
Steichen, Jon M.
de Taeye, Steven W.
Tokatlian, Talar
Torrents de la Peña, Alba
Butera, Salvatore T.
LaBranche, Celia C.
Montefiori, David C.
Silvestri, Guido
Wilson, Ian A.
Irvine, Darrell J.
Sanders, Rogier W.
Schief, William R.
Ward, Andrew B.
Wyatt, Richard T.
Barouch, Dan H.
Crotty, Shane
Burton, Dennis R.
author_sort Pauthner, Matthias
collection PubMed
description The development of stabilized recombinant HIV envelope trimers that mimic the virion surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV vaccine. However, there is limited experience with recombinant trimers as immunogens in nonhuman primates, which are typically used as a model for humans. Here, we tested multiple immunogens and immunization strategies head-to-head to determine their impact on the quantity, quality, and kinetics of autologous tier 2 nAb development. A bilateral, adjuvanted, subcutaneous immunization protocol induced reproducible tier 2 nAb responses after only two immunizations 8 weeks apart, and these were further enhanced by a third immunization with BG505 SOSIP trimer. We identified immunogens that minimized non-neutralizing V3 responses and demonstrated that continuous immunogen delivery could enhance nAb responses. nAb responses were strongly associated with germinal center reactions, as assessed by lymph node fine needle aspiration. This study provides a framework for preclinical and clinical vaccine studies targeting nAb elicitation.
format Online
Article
Text
id pubmed-5483234
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cell Press
record_format MEDLINE/PubMed
spelling pubmed-54832342017-06-29 Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches Pauthner, Matthias Havenar-Daughton, Colin Sok, Devin Nkolola, Joseph P. Bastidas, Raiza Boopathy, Archana V. Carnathan, Diane G. Chandrashekar, Abishek Cirelli, Kimberly M. Cottrell, Christopher A. Eroshkin, Alexey M. Guenaga, Javier Kaushik, Kirti Kulp, Daniel W. Liu, Jinyan McCoy, Laura E. Oom, Aaron L. Ozorowski, Gabriel Post, Kai W. Sharma, Shailendra K. Steichen, Jon M. de Taeye, Steven W. Tokatlian, Talar Torrents de la Peña, Alba Butera, Salvatore T. LaBranche, Celia C. Montefiori, David C. Silvestri, Guido Wilson, Ian A. Irvine, Darrell J. Sanders, Rogier W. Schief, William R. Ward, Andrew B. Wyatt, Richard T. Barouch, Dan H. Crotty, Shane Burton, Dennis R. Immunity Resource The development of stabilized recombinant HIV envelope trimers that mimic the virion surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV vaccine. However, there is limited experience with recombinant trimers as immunogens in nonhuman primates, which are typically used as a model for humans. Here, we tested multiple immunogens and immunization strategies head-to-head to determine their impact on the quantity, quality, and kinetics of autologous tier 2 nAb development. A bilateral, adjuvanted, subcutaneous immunization protocol induced reproducible tier 2 nAb responses after only two immunizations 8 weeks apart, and these were further enhanced by a third immunization with BG505 SOSIP trimer. We identified immunogens that minimized non-neutralizing V3 responses and demonstrated that continuous immunogen delivery could enhance nAb responses. nAb responses were strongly associated with germinal center reactions, as assessed by lymph node fine needle aspiration. This study provides a framework for preclinical and clinical vaccine studies targeting nAb elicitation. Cell Press 2017-06-20 /pmc/articles/PMC5483234/ /pubmed/28636956 http://dx.doi.org/10.1016/j.immuni.2017.05.007 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Resource
Pauthner, Matthias
Havenar-Daughton, Colin
Sok, Devin
Nkolola, Joseph P.
Bastidas, Raiza
Boopathy, Archana V.
Carnathan, Diane G.
Chandrashekar, Abishek
Cirelli, Kimberly M.
Cottrell, Christopher A.
Eroshkin, Alexey M.
Guenaga, Javier
Kaushik, Kirti
Kulp, Daniel W.
Liu, Jinyan
McCoy, Laura E.
Oom, Aaron L.
Ozorowski, Gabriel
Post, Kai W.
Sharma, Shailendra K.
Steichen, Jon M.
de Taeye, Steven W.
Tokatlian, Talar
Torrents de la Peña, Alba
Butera, Salvatore T.
LaBranche, Celia C.
Montefiori, David C.
Silvestri, Guido
Wilson, Ian A.
Irvine, Darrell J.
Sanders, Rogier W.
Schief, William R.
Ward, Andrew B.
Wyatt, Richard T.
Barouch, Dan H.
Crotty, Shane
Burton, Dennis R.
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title_full Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title_fullStr Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title_full_unstemmed Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title_short Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
title_sort elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by hiv envelope trimer immunization using optimized approaches
topic Resource
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483234/
https://www.ncbi.nlm.nih.gov/pubmed/28636956
http://dx.doi.org/10.1016/j.immuni.2017.05.007
work_keys_str_mv AT pauthnermatthias elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT havenardaughtoncolin elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT sokdevin elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT nkololajosephp elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT bastidasraiza elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT boopathyarchanav elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT carnathandianeg elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT chandrashekarabishek elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT cirellikimberlym elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT cottrellchristophera elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT eroshkinalexeym elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT guenagajavier elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT kaushikkirti elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT kulpdanielw elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT liujinyan elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT mccoylaurae elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT oomaaronl elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT ozorowskigabriel elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT postkaiw elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT sharmashailendrak elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT steichenjonm elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT detaeyestevenw elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT tokatliantalar elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT torrentsdelapenaalba elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT buterasalvatoret elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT labrancheceliac elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT montefioridavidc elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT silvestriguido elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT wilsoniana elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT irvinedarrellj elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT sandersrogierw elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT schiefwilliamr elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT wardandrewb elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT wyattrichardt elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT barouchdanh elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT crottyshane elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches
AT burtondennisr elicitationofrobusttier2neutralizingantibodyresponsesinnonhumanprimatesbyhivenvelopetrimerimmunizationusingoptimizedapproaches